A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients

被引：10
作者：
Gui, Yu [1 ]
Xu, Shuman [1 ]
Yang, Xi [1 ]
Gu, Lu [2 ,3 ]
Zhang, Ze [2 ,3 ]
Luo, Xiangdong [2 ,3 ]
Chen, Li [1 ,3 ]
机构：
[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China
[2] Third Mil Med Univ, Burn Res Inst, Southwest Hosp, Chongqing 400038, Peoples R China
[3] Chongqing Key Lab Dis Prote, Natl Key Lab Trauma & Burns, Chongqing, Peoples R China
来源：
BIOMARKERS IN MEDICINE | 2016年 / 10卷 / 07期
基金：
中国国家自然科学基金;
关键词：
biomarkers; chemotherapy; meta-analysis; prognosis; triple-negative breast cancer; ANTHRACYCLINE-BASED CHEMOTHERAPY; INTERNATIONAL EXPERT CONSENSUS; NEOADJUVANT CHEMOTHERAPY; GROWTH-FACTOR; ADJUVANT CHEMOTHERAPY; CELL-CYCLE; PROMOTER METHYLATION; PRIMARY THERAPY; FALLOPIAN-TUBE; OVARIAN-CANCER;
D O I：
10.2217/bmm-2015-0064
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Identification of biomarkers that has the ability to predict triple negative breast cancer (TNBC) prognosis especially in patients undergoing chemotherapy is very important. Methods: The cohort studies that reported association between chemotherapy biomarker expression and survival outcome in TNBC patients were included in our analysis. Results: The promising markers that emerged for the prediction of disease-free survival and overall survival included Ki67, BRCA1 methylation and LC3B. Furthermore, Ki67 appeared to be also significantly associated with worse disease-free survival in TNBC patients who received anthracycline-based chemotherapy. Conclusion: This meta-analysis demonstrated that in TNBC patients receiving chemotherapy, Ki67 is a predictor for poor prognosis, BRCA1 methylation and LC3B are also potential prognostic markers. In addition, the TNBC patients with high Ki67 expression seems to display resistance to anthracycline-based chemotherapy.
引用
收藏
页码：771 / 790
页数：20
相关论文
共 77 条
  • [1] Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
    Abdel-Fatah, T. M. A.
    Perry, C.
    Dickinson, P.
    Ball, G.
    Moseley, P.
    Madhusudan, S.
    Ellis, I. O.
    Chan, S. Y. T.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (11) : 2801 - 2807
  • [2] Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience
    Asleh-Aburaya, Karama
    Fried, Georgeta
    [J]. SPRINGERPLUS, 2015, 4 : 1 - 7
  • [3] Ataseven B, 2013, ANTICANCER RES, V33, P3759
  • [4] A genetic epidemiological study of carcinoma of the fallopian tube
    Aziz, S
    Kuperstein, G
    Rosen, B
    Cole, D
    Nedelcu, R
    McLaughlin, J
    Narod, SA
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 80 (03) : 341 - 345
  • [5] Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
    Bayraktar, Soley
    Gutierrez-Barrera, Angelica M.
    Liu, Diane
    Tasbas, Tunc
    Akar, Ugur
    Litton, Jennifer K.
    Lin, E.
    Albarracin, Constance T.
    Meric-Bernstam, Funda
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Arun, Banu K.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (01) : 145 - 153
  • [6] Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review
    Bernier, Jacques
    Poortmans, Philip
    [J]. BREAST, 2015, 24 (02) : 100 - 106
  • [7] p53 in breast cancer subtypes and new insights into response to chemotherapy
    Bertheau, Philippe
    Lehmann-Che, Jacqueline
    Varna, Mariana
    Dumay, Anne
    Poirot, Brigitte
    Porcher, Raphael
    Turpin, Elisabeth
    Plassa, Louis-Francois
    de Roquancourt, Anne
    Bourstyn, Edwige
    de Cremoux, Patricia
    Janin, Anne
    Giacchetti, Sylvie
    Espie, Marc
    de The, Hugues
    [J]. BREAST, 2013, 22 : S27 - S29
  • [8] Billgren AM, 1999, ACTA ONCOL, V38, P597
  • [9] P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas
    Bogina, Giuseppe S.
    Lunardi, Gianluigi
    Marcolini, Lisa
    Brunelli, Matte
    Bortesi, Laura
    Marconi, Marcella
    Coati, Francesca
    Valerio, Matteo
    Guerriero, Massimo
    Massocco, Alberto
    Pegoraro, Maria C.
    Zamboni, Giuseppe
    [J]. MODERN PATHOLOGY, 2014, 27 (02) : 204 - 213
  • [10] Brown RW, 1996, CLIN CANCER RES, V2, P585
12345678